Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era
2023-01-01 Facchinetti, F.; Janne, P. A.; Tiseo, M.
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
2024-01-01 Ciammella, P.; Cozzi, S.; Borghetti, P.; Galaverni, M.; Nardone, V.; Ruggieri, M. P.; Sepulcri, M.; Scotti, V.; Bruni, A.; Zanelli, F.; Piro, R.; Tagliavini, E.; Botti, A.; Iori, F.; Ali, E.; Bennati, C.; Tiseo, M.
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3)
2021-01-01 Gelsomino, F.; Tiseo, M.; Barbieri, F.; Riccardi, F.; Cavanna, L.; Frassoldati, A.; Delmonte, A.; Longo, L.; Dazzi, C.; Cinieri, S.; Colantonio, I.; Sperandi, F.; Lamberti, G.; Brocchi, S.; Tofani, L.; Boni, L.; Ardizzoni, A.
Non-small-cell lung cancer: how to manage BRAF-mutated disease
2023-01-01 Guaitoli, G.; Zullo, L.; Tiseo, M.; Dankner, M.; Rose, A. A. N.; Facchinetti, F.
The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice
2022-01-01 De Maglio, G.; Pasello, G.; Dono, M.; Fiorentino, M.; Follador, A.; Sciortino, M.; Malapelle, U.; Tiseo, M.
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making
2024-01-01 Perrone, F.; Facchinetti, F.; Pellegrino, B.; Minari, R.; Gnetti, L.; Azzoni, C.; Bottarelli, L.; Campanini, N.; Grau-Bejar, J. F.; Mingozzi, A.; Cognigni, V.; Tiseo, M.
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016
2025-01-01 Gelsomino, F.; Boni, L.; Tiseo, M.; Ricciardi, S.; D'Armiento, Rocco; Cortinovis, D. L.; Proietto, M.; Cogoni, A.; Pasello, G.; Camerini, A.; Sperandi, F.; Colantonio, I.; Metro, G.; Mazzoni, F.; Baldini, E.; Veccia, A.; Bennicelli, E.; Cecilia Bettini, A.; Tognetto, M.; Ardizzoni, A.
Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective
2021-01-01 Malapelle, U.; Tiseo, M.; Vivancos, A.; Kapp, J.; Serrano, M. J.; Tiemann, M.
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database
2024-01-01 Reale, M. L.; Passiglia, F.; Cappuzzo, F.; Minuti, G.; Occhipinti, M.; Bulotta, A.; Delmonte, A.; Sini, C.; Galetta, D.; Roca, E.; Pelizzari, G.; Cortinovis, D.; Gariazzo, E.; Pilotto, S.; Citarella, F.; Bria, E.; Muscolino, P.; Pozzessere, D.; Carta, A.; Pignataro, D.; Calvetti, L.; Leone, F.; Banini, M.; Di Micco, C.; Baldini, E.; Favaretto, A.; Malapelle, U.; Novello, S.; Pasello, G.; Tiseo, M.
Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
2019-01-01 Ravasio, R.; Tiseo, M.; Pradelli, L.; Bellone, M.; Gervasi, A.; Coffani, M.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2024-01-01 Borghaei, H.; De Marinis, F.; Dumoulin, D.; Reynolds, C.; Theelen, W. S. M. E.; Percent, I.; Gutierrez Calderon, V.; Johnson, M. L.; Madroszyk-Flandin, A.; Garon, E. B.; He, K.; Planchard, D.; Reck, M.; Popat, S.; Herbst, R. S.; Leal, T. A.; Shazer, R. L.; Yan, X.; Harrigan, R.; Peters, S.; Abdel-Karim, I.; Abdelsalam, M.; Addeo, A.; Aguado, C.; Alexander, P.; Alt, J.; Azzi, G.; Balaraman, R.; Biesma, B.; Blackhall, F.; Bohnet, S.; Boleti, E.; Borghaei, H.; Bradbury, P.; Brighenti, M.; Campbell, N.; Campbell, T.; Canon, J. -L.; Cappuzzo, F.; Costa, E. C.; Cavanna, L.; Cetnar, J.; Chella, A.; Chouaid, C.; Christoph, D.; Castan, J. C.; Dakhil, S.; De Castro Carpeno, F. J.; De Marinis, F.; Delmonte, A.; Demedts, I.; Demey, W.; Dits, J.; Del Pilar Diz Tain, M.; Gomez, M. D.; Dorius, T.; Dumoulin, D.; Duruisseaux, M.; Eaton, K.; Gonzalez, E. E.; Evans, D.; Faehling, M.; Farrell, N.; Feinstein, T.; Font, E. F.; Garcia Campelo, M. R.; Garon, E.; Garrido Lopez, M. P.; Germonpre, P.; Gersten, T.; Cao, M. G.; Gopaluni, S.; Greillier, L.; Grossi, F.; Guisier, F.; Gurubhagavatula, S.; Calderon, V. G.; Hakimian, D.; Hall, R.; Hao, D.; Harris, R.; Hashemi, S.; He, K.; Hendriks, L.; Huang, C.; Ibrahim, E.; Jain, S.; Johnson, M.; Jones, B.; Jones, M.; Juan Vidal, O. J.; Juergens, R.; Kaderbhai, C.; Kastelijn, E. A. L.; Keresztes, R.; Kio, E.; Kokowski, K.; Konduri, K.; Kulkarni, S.; Kuon, J.; Kurkjian, C.; Labbe, C.; Lerner, R.; Lim, F.; Madroszyk-Flandin, A.; Marathe, O.; Martincic, D.; Mcclay, E.; Mcintyre, K.; Mekhail, T.; Misino, A.; Molinier, O.; Morabito, A.; Morocz, E.; Muller, V.; Nagy, T.; Nguyen, A. V.; Nidhiry, E.; Okazaki, I.; Ortega-Granados, A. L.; Ostoros, G.; Oubre, D.; Owen, S.; Pachipala, K.; Park, D.; Patel, P.; Percent, I.; Perol, M.; Peters, S.; Piet, B.; Planchard, D.; Polychronis, A.; Aix, S. P.; Pons-Tostivint, E.; Pulla, M. P.; Quantin, X.; Quere, G.; Rafique, N.; Ramaekers, R.; Reck, M.; Reiman, A.; Reinmuth, N.; Reynolds, C.; Rodriguez-Abreu, D.; Romano, G.; Roque, T.; Salzberg, M.; Sanborn, R.; Sandiego, S.; Schaefer, E.; Schreeder, M.; Seetharamu, N.; Seneviratne, L.; Shah, P.; Shunyakov, L.; Slater, D.; Parra, H. S.; Stigt, J.; Stilwill, J.; Su, J.; Surmont, V.; Swink, A.; Szalai, Z.; Talbot, T.; Garcia, A. T.; Theelen, W.; Thompson, J.; Tiseo, M.; Uprety, D.; Uyeki, J.; Van Der Leest, K. C.; Van Ho, A.; Van Putten, J.; Estevez, S. V.; Veatch, A.; Vergnenegre, A.; Ward, P.; Weise, A.; Weiss, M.; Whitehurst, M.; Zai, S.; Zalcman, G.; Zuniga, R.
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC
2024-01-01 Perrone, F.; Leonetti, A.; Tiseo, M.; Facchinetti, F.
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database
2024-01-01 Malapelle, U.; Passiglia, F.; Pepe, F.; Pisapia, P.; Lucia Reale, M.; Cortinovis, D.; Fraggetta, F.; Galetta, D.; Garbo, E.; Graziano, P.; Pagni, F.; Pasello, G.; Piovano, P.; Pilotto, S.; Tiseo, M.; Genova, C.; Righi, L.; Troncone, G.; Novello, S.
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P
2022-01-01 Guida, A.; Tassi, V.; Facchinetti, F.; Marchetti, G.; Caprera, C.; Ragusa, M.; Tiseo, M.; Bracarda, S.
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges
2024-01-01 Cortinovis, D. L.; Leonetti, A.; Morabito, A.; Sala, L.; Tiseo, M.
Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)
2024-01-01 Bruni, A.; Scotti, V.; Zerella, M. A.; Bertolini, F.; Imbrescia, J.; Olmetto, E.; Bennati, C.; Cuccia, F.; Miele, M.; Giaj-Levra, N.; Tiseo, M.; Ciammella, P.; Vagge, S.; Galaverni, M.; Pontoriero, A.; Badellino, S.; Spoto, R.; Ali, E.; Borghetti, P.
Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-01-01 Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Caminiti, C.; Tiseo, M.
BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report
2024-01-01 Rossi, G.; Righi, L.; Barbisan, F.; Tiseo, M.; Spagnolo, P.; Grosso, F.; Pisapia, P.; Malapelle, U.; Sculco, M.; Dianzani, I.; Abate-Daga, L.; Davolio, M. C.; Ceresoli, G. L.; Galetta, D.; Pasello, G.; Novello, S.; Bironzo, P.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-01-01 Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Bordi, P.; Bria, E.; Vita, E.; Gelsomino, F.; De Giglio, A.; Gelibter, A.; Siringo, M.; Mazzoni, F.; Caliman, E.; Genova, C.; Bertolini, F.; Guaitoli, G.; Passiglia, F.; Delcuratolo, M. D.; Montrone, M.; Cerea, G.; Pasello, G.; Roca, E.; Belluomini, L.; Cecere, F. L.; Guida, A.; Manzo, A.; Adamo, V.; Rastelli, F.; Bulotta, A.; Citarella, F.; Toschi, L.; Zoratto, F.; Cortinovis, D. L.; Berardi, R.; Follador, A.; Carta, A.; Camerini, A.; Salerno, F.; Silva, R. R.; Baldini, E.; Cortellini, A.; Brighenti, M.; Santoni, M.; Malorgio, F.; Caminiti, C.; Tiseo, M.
Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
2025-01-01 Ciammella, P.; Iori, F.; Borghetti, P.; Galaverni, M.; Ali, E.; Tiseo, M.; Pagano, M.; Sepulcri, M.; Scotti, V.; Giajlevra, N.; Marcenaro, M.; Simoni, N.; Nardone, V.; Botti, A.; Cozzi, S.; Bruni, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era | 1-gen-2023 | Facchinetti, F.; Janne, P. A.; Tiseo, M. | |
| Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis | 1-gen-2024 | Ciammella, P.; Cozzi, S.; Borghetti, P.; Galaverni, M.; Nardone, V.; Ruggieri, M. P.; Sepulcri, M.; Scotti, V.; Bruni, A.; Zanelli, F.; Piro, R.; Tagliavini, E.; Botti, A.; Iori, F.; Ali, E.; Bennati, C.; Tiseo, M. | |
| Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) | 1-gen-2021 | Gelsomino, F.; Tiseo, M.; Barbieri, F.; Riccardi, F.; Cavanna, L.; Frassoldati, A.; Delmonte, A.; Longo, L.; Dazzi, C.; Cinieri, S.; Colantonio, I.; Sperandi, F.; Lamberti, G.; Brocchi, S.; Tofani, L.; Boni, L.; Ardizzoni, A. | |
| Non-small-cell lung cancer: how to manage BRAF-mutated disease | 1-gen-2023 | Guaitoli, G.; Zullo, L.; Tiseo, M.; Dankner, M.; Rose, A. A. N.; Facchinetti, F. | |
| The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice | 1-gen-2022 | De Maglio, G.; Pasello, G.; Dono, M.; Fiorentino, M.; Follador, A.; Sciortino, M.; Malapelle, U.; Tiseo, M. | |
| Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making | 1-gen-2024 | Perrone, F.; Facchinetti, F.; Pellegrino, B.; Minari, R.; Gnetti, L.; Azzoni, C.; Bottarelli, L.; Campanini, N.; Grau-Bejar, J. F.; Mingozzi, A.; Cognigni, V.; Tiseo, M. | |
| An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016 | 1-gen-2025 | Gelsomino, F.; Boni, L.; Tiseo, M.; Ricciardi, S.; D'Armiento, Rocco; Cortinovis, D. L.; Proietto, M.; Cogoni, A.; Pasello, G.; Camerini, A.; Sperandi, F.; Colantonio, I.; Metro, G.; Mazzoni, F.; Baldini, E.; Veccia, A.; Bennicelli, E.; Cecilia Bettini, A.; Tognetto, M.; Ardizzoni, A. | |
| Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective | 1-gen-2021 | Malapelle, U.; Tiseo, M.; Vivancos, A.; Kapp, J.; Serrano, M. J.; Tiemann, M. | |
| MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database | 1-gen-2024 | Reale, M. L.; Passiglia, F.; Cappuzzo, F.; Minuti, G.; Occhipinti, M.; Bulotta, A.; Delmonte, A.; Sini, C.; Galetta, D.; Roca, E.; Pelizzari, G.; Cortinovis, D.; Gariazzo, E.; Pilotto, S.; Citarella, F.; Bria, E.; Muscolino, P.; Pozzessere, D.; Carta, A.; Pignataro, D.; Calvetti, L.; Leone, F.; Banini, M.; Di Micco, C.; Baldini, E.; Favaretto, A.; Malapelle, U.; Novello, S.; Pasello, G.; Tiseo, M. | |
| Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer | 1-gen-2019 | Ravasio, R.; Tiseo, M.; Pradelli, L.; Bellone, M.; Gervasi, A.; Coffani, M. | |
| SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer | 1-gen-2024 | Borghaei, H.; De Marinis, F.; Dumoulin, D.; Reynolds, C.; Theelen, W. S. M. E.; Percent, I.; Gutierrez Calderon, V.; Johnson, M. L.; Madroszyk-Flandin, A.; Garon, E. B.; He, K.; Planchard, D.; Reck, M.; Popat, S.; Herbst, R. S.; Leal, T. A.; Shazer, R. L.; Yan, X.; Harrigan, R.; Peters, S.; Abdel-Karim, I.; Abdelsalam, M.; Addeo, A.; Aguado, C.; Alexander, P.; Alt, J.; Azzi, G.; Balaraman, R.; Biesma, B.; Blackhall, F.; Bohnet, S.; Boleti, E.; Borghaei, H.; Bradbury, P.; Brighenti, M.; Campbell, N.; Campbell, T.; Canon, J. -L.; Cappuzzo, F.; Costa, E. C.; Cavanna, L.; Cetnar, J.; Chella, A.; Chouaid, C.; Christoph, D.; Castan, J. C.; Dakhil, S.; De Castro Carpeno, F. J.; De Marinis, F.; Delmonte, A.; Demedts, I.; Demey, W.; Dits, J.; Del Pilar Diz Tain, M.; Gomez, M. D.; Dorius, T.; Dumoulin, D.; Duruisseaux, M.; Eaton, K.; Gonzalez, E. E.; Evans, D.; Faehling, M.; Farrell, N.; Feinstein, T.; Font, E. F.; Garcia Campelo, M. R.; Garon, E.; Garrido Lopez, M. P.; Germonpre, P.; Gersten, T.; Cao, M. G.; Gopaluni, S.; Greillier, L.; Grossi, F.; Guisier, F.; Gurubhagavatula, S.; Calderon, V. G.; Hakimian, D.; Hall, R.; Hao, D.; Harris, R.; Hashemi, S.; He, K.; Hendriks, L.; Huang, C.; Ibrahim, E.; Jain, S.; Johnson, M.; Jones, B.; Jones, M.; Juan Vidal, O. J.; Juergens, R.; Kaderbhai, C.; Kastelijn, E. A. L.; Keresztes, R.; Kio, E.; Kokowski, K.; Konduri, K.; Kulkarni, S.; Kuon, J.; Kurkjian, C.; Labbe, C.; Lerner, R.; Lim, F.; Madroszyk-Flandin, A.; Marathe, O.; Martincic, D.; Mcclay, E.; Mcintyre, K.; Mekhail, T.; Misino, A.; Molinier, O.; Morabito, A.; Morocz, E.; Muller, V.; Nagy, T.; Nguyen, A. V.; Nidhiry, E.; Okazaki, I.; Ortega-Granados, A. L.; Ostoros, G.; Oubre, D.; Owen, S.; Pachipala, K.; Park, D.; Patel, P.; Percent, I.; Perol, M.; Peters, S.; Piet, B.; Planchard, D.; Polychronis, A.; Aix, S. P.; Pons-Tostivint, E.; Pulla, M. P.; Quantin, X.; Quere, G.; Rafique, N.; Ramaekers, R.; Reck, M.; Reiman, A.; Reinmuth, N.; Reynolds, C.; Rodriguez-Abreu, D.; Romano, G.; Roque, T.; Salzberg, M.; Sanborn, R.; Sandiego, S.; Schaefer, E.; Schreeder, M.; Seetharamu, N.; Seneviratne, L.; Shah, P.; Shunyakov, L.; Slater, D.; Parra, H. S.; Stigt, J.; Stilwill, J.; Su, J.; Surmont, V.; Swink, A.; Szalai, Z.; Talbot, T.; Garcia, A. T.; Theelen, W.; Thompson, J.; Tiseo, M.; Uprety, D.; Uyeki, J.; Van Der Leest, K. C.; Van Ho, A.; Van Putten, J.; Estevez, S. V.; Veatch, A.; Vergnenegre, A.; Ward, P.; Weise, A.; Weiss, M.; Whitehurst, M.; Zai, S.; Zalcman, G.; Zuniga, R. | |
| Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC | 1-gen-2024 | Perrone, F.; Leonetti, A.; Tiseo, M.; Facchinetti, F. | |
| The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database | 1-gen-2024 | Malapelle, U.; Passiglia, F.; Pepe, F.; Pisapia, P.; Lucia Reale, M.; Cortinovis, D.; Fraggetta, F.; Galetta, D.; Garbo, E.; Graziano, P.; Pagni, F.; Pasello, G.; Piovano, P.; Pilotto, S.; Tiseo, M.; Genova, C.; Righi, L.; Troncone, G.; Novello, S. | |
| Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P | 1-gen-2022 | Guida, A.; Tassi, V.; Facchinetti, F.; Marchetti, G.; Caprera, C.; Ragusa, M.; Tiseo, M.; Bracarda, S. | |
| Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges | 1-gen-2024 | Cortinovis, D. L.; Leonetti, A.; Morabito, A.; Sala, L.; Tiseo, M. | |
| Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) | 1-gen-2024 | Bruni, A.; Scotti, V.; Zerella, M. A.; Bertolini, F.; Imbrescia, J.; Olmetto, E.; Bennati, C.; Cuccia, F.; Miele, M.; Giaj-Levra, N.; Tiseo, M.; Ciammella, P.; Vagge, S.; Galaverni, M.; Pontoriero, A.; Badellino, S.; Spoto, R.; Ali, E.; Borghetti, P. | |
| Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed | 1-gen-2024 | Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Caminiti, C.; Tiseo, M. | |
| BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report | 1-gen-2024 | Rossi, G.; Righi, L.; Barbisan, F.; Tiseo, M.; Spagnolo, P.; Grosso, F.; Pisapia, P.; Malapelle, U.; Sculco, M.; Dianzani, I.; Abate-Daga, L.; Davolio, M. C.; Ceresoli, G. L.; Galetta, D.; Pasello, G.; Novello, S.; Bironzo, P. | |
| Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed | 1-gen-2024 | Leonetti, A.; Perrone, F.; Puntoni, M.; Maglietta, G.; Bordi, P.; Bria, E.; Vita, E.; Gelsomino, F.; De Giglio, A.; Gelibter, A.; Siringo, M.; Mazzoni, F.; Caliman, E.; Genova, C.; Bertolini, F.; Guaitoli, G.; Passiglia, F.; Delcuratolo, M. D.; Montrone, M.; Cerea, G.; Pasello, G.; Roca, E.; Belluomini, L.; Cecere, F. L.; Guida, A.; Manzo, A.; Adamo, V.; Rastelli, F.; Bulotta, A.; Citarella, F.; Toschi, L.; Zoratto, F.; Cortinovis, D. L.; Berardi, R.; Follador, A.; Carta, A.; Camerini, A.; Salerno, F.; Silva, R. R.; Baldini, E.; Cortellini, A.; Brighenti, M.; Santoni, M.; Malorgio, F.; Caminiti, C.; Tiseo, M. | |
| Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial) | 1-gen-2025 | Ciammella, P.; Iori, F.; Borghetti, P.; Galaverni, M.; Ali, E.; Tiseo, M.; Pagano, M.; Sepulcri, M.; Scotti, V.; Giajlevra, N.; Marcenaro, M.; Simoni, N.; Nardone, V.; Botti, A.; Cozzi, S.; Bruni, A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista71941
- 2 Contributo in volume (Capitolo ...1
- 7 Altro1
Data di pubblicazione
- In corso di stampa64
- 2020 - 202617029
- 2010 - 201923027
- 2000 - 200918346
- 1990 - 19998892
- 1980 - 19893844
- 1970 - 1979711
- 1965 - 196930
Editore
- MDPI972
- Elsevier Ltd761
- Elsevier B.V.652
- MDPI AG497
- Elsevier392
- John Wiley and Sons Inc327
- Springer323
- Multidisciplinary Digital Publish...309
- Springer Science and Business Med...300
- Elsevier Inc.264
Rivista
- ACTA BIO-MEDICA DE L'ATENEO PARMENSE933
- PLOS ONE384
- ANNALI DELLA FACOLTÀ DI MEDICINA ...348
- SCIENTIFIC REPORTS282
- AREA262
- INTERNATIONAL JOURNAL OF MOLECULA...196
- DOCTOR. OS183
- ACTA BIOMEDICA182
- NUTRIENTS180
- PHYSICAL REVIEW. B, CONDENSED MAT...169
Serie
- KEY ENGINEERING MATERIALS1
Keyword
- Humans2917
- Female1597
- Male1493
- Middle Aged904
- Adult898
- Aged760
- Animals652
- Italy592
- Medicine (all)464
- COVID-19459
Lingua
- eng43555
- ita9134
- fre232
- spa124
- ger99
- und61
- enm49
- rus41
- grc33
- por33
Accesso al fulltext
- no fulltext58628
- reserved8054
- open3769
- partially open822
- restricted667
- embargoed2
- mixed1